Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61.

View in: PubMed

subject areas

Administration, Intravenous
Adult
Aged
Alemtuzumab
Allografts
Antibodies, Monoclonal, Humanized
Female
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Injections, Subcutaneous
Male
Melphalan
Middle Aged
Transplantation Conditioning
Unrelated Donors
Vidarabine

authors with profiles

Koen Van Besien